US2014288018A1PendingUtilityA1

Methods for predicting the response to anti-cancer treatment with an agonist of tlr7 or an agonist of tlr8

47
Assignee: INST NAT SANTE RECH MEDPriority: Aug 20, 2008Filed: Mar 27, 2014Published: Sep 25, 2014
Est. expiryAug 20, 2028(~2.1 yrs left)· nominal 20-yr term from priority
Inventors:Julien CherfilsHerve FridmanIsabelle Cremer
A61K 31/437C12Q 2600/106G01N 2800/52G01N 2333/705A61K 31/708A61P 35/00C12Q 1/6881G01N 33/57557G01N 33/5759G01N 33/5752G01N 33/575C12Q 1/6886G01N 33/574
47
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to methods for predicting the response to treatment with an agonist of TLR7, or an agonist of TLR8 or an anti-cancer agent for treating cancer, in particular non-small cell lung cancer comprising the step of detecting the expression of TLR7 or TLR8 in cancer cells of said patient.

Claims

exact text as granted — not AI-modified
1 . A method for predicting the response to treatment with an anti-cancer agent in a patient suffering from cancer, comprising the step of detecting the expression of TLR7 or TLR8 in cancer cells of said patient, wherein the presence of TLR7 or TLR8 in cancer cells is indicative of poor response to treatment. 
     
     
         2 . The method of  claim 1 , wherein said method is A for predicting the response to a combined treatment with an anti-cancer agent and an agonist of TLR7, comprising the step of detecting the expression of TLR7 in cancer cells of said patient, wherein the presence of TLR7 in cancer cells in indicative of poor response to treatment. 
     
     
         3 . The method of  claim 1 , wherein said method is for predicting response to a combined treatment with an anti-cancer agent and an agonist of TLR8 in a patient suffering from cancer, comprising the step of detecting the expression of TLR8 in cancer cells of said patient, wherein the presence of TLR8 in cancer cells is indicative of poor response to treatment. 
     
     
         4 . The method of  claim 1 , wherein said method is for predicting the response to treatment with an agonist of TLR7 in a patient suffering from cancer, comprising the step of detecting the expression of TLR7 in cancer cells of said patient, wherein the presence of TLR7 in cancer cells is indicative of poor response to treatment. 
     
     
         5 . The method of  claim 1 , wherein said method is for predicting the response to treatment with an agonist of TLR8 in a patient suffering from cancer, comprising the step of detecting the expression of TLR8 in cancer cells of said patient, wherein the presence of TLR8 in cancer cells is indicative of poor response to treatment. 
     
     
         6 . A method for treating a cancer patient comprising administering a therapeutically effective amount of an agonist of TLR7 and wherein said patient does not express TLR7 in cancer cells. 
     
     
         7 . A method for treating a cancer patient comprising administering a therapeutically effective amount of an agonist of TLR8 and wherein said patient does not express TLR8 in cancer cells. 
     
     
         8 . The method of  claim 7  wherein said agonist is used in combination with an anti-cancer agent. 
     
     
         9 - 15 . (canceled) 
     
     
         16 . The method of  claim 1 , wherein said cancer is selected from the group consisting of lung cancer, breast cancer, colorectal cancer, renal carcinoma, prostate cancer, melanoma, and lymphoma. 
     
     
         17 . The method of  claim 2 , wherein said cancer is selected from the group consisting of lung cancer, breast cancer, colorectal cancer, renal carcinoma, prostate cancer, melanoma, and lymphoma. 
     
     
         18 . The method of  claim 3 , wherein said cancer is selected from the group consisting of lung cancer, breast cancer, colorectal cancer, renal carcinoma, prostate cancer, melanoma, and lymphoma. 
     
     
         19 . The method of  claim 4 , wherein said cancer is selected from the group consisting of lung cancer, breast cancer, colorectal cancer, renal carcinoma, prostate cancer, melanoma, and lymphoma. 
     
     
         20 . The method of  claim 5 , wherein said cancer is selected from the group consisting of lung cancer, breast cancer, colorectal cancer, renal carcinoma, prostate cancer, melanoma, and lymphoma. 
     
     
         21 . The method of  claim 6  wherein said agonist is used in combination with an anti-cancer agent. 
     
     
         22 . The method of  claim 6 , wherein said cancer is selected from the group consisting of lung cancer, breast cancer, colorectal cancer, renal carcinoma, prostate cancer, melanoma, and lymphoma. 
     
     
         23 . The method of  claim 7 , wherein said cancer is selected from the group consisting of lung cancer, breast cancer, colorectal cancer, renal carcinoma, prostate cancer, melanoma, and lymphoma.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.